Efficacy and safety of Remimazom for sedation in patients with delirium in ICU

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100049199

Enrollment

Unknown

Registered

2021-07-25

Start date

2022-07-21

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ICU Patients

Interventions

Group 1:Dexmedetomidine

Group 2:Remazolam

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Continuous admission of non-intubated patients in ICU; 2. CAM-ICU positive, RASS score > 1 point; 3. Aged 18 to 60 years; 4. Obtain informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. Patients with benzodiazepine allergy, muscle weakness, and underlying mental illness; 3. Patients with severe hepatic and renal insufficiency.

Design outcomes

Primary

Measure	Time frame
sedation time;	—

Secondary

Measure	Time frame
blood pressure;heart rate;Richmond Agitation-Sedation Scale;blood oxygen;	—

Countries

China

Contacts

Public ContactHe Bin

Shanghai Chest Hospital

1130109045@qq.com+86 18205192915

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026